Seaport Therapeutics, Inc. Common Stock (SPTX) - Total Liabilities
Based on the latest financial reports, Seaport Therapeutics, Inc. Common Stock (SPTX) has total liabilities worth $19.08 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Seaport Therapeutics, Inc. Common Stock long-term investment intensity to see how much of total assets are deployed in long-term investments.
Seaport Therapeutics, Inc. Common Stock - Total Liabilities Trend (2024–2025)
This chart illustrates how Seaport Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see SPTX total assets.
Seaport Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Seaport Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hannstar Display Corp
TW:6116
|
Taiwan | NT$9.58 Billion |
|
Berkshire Hills Bancorp Inc
NYSE:BHLB
|
USA | $10.81 Billion |
|
Capital Clean Energy Carriers Corp.
NASDAQ:CCEC
|
USA | $2.60 Billion |
|
Zhejiang Fulai New Material Co.Ltd.
SHG:605488
|
China | CN¥1.98 Billion |
|
Adriatic Metals Plc
F:3FN
|
Germany | €192.27 Million |
|
Kestra Medical Technologies, Ltd. Common Stock
NASDAQ:KMTS
|
USA | $91.35 Million |
|
Shandong Weigao Orthopaedic Device Co. Ltd. A
SHG:688161
|
China | CN¥961.73 Million |
|
Taiji Computer Corp Ltd
SHE:002368
|
China | CN¥10.85 Billion |
Liability Composition Analysis (2024–2025)
This chart breaks down Seaport Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See SPTX net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 18.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Seaport Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Seaport Therapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual total liabilities of Seaport Therapeutics, Inc. Common Stock from 2024 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $341.55 Million | +0.27% |
| 2024-12-31 | $340.63 Million | -- |
About Seaport Therapeutics, Inc. Common Stock
Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company's lead product candidate, GlyphAllo (SPT-30… Read more